Transfusions have begun in EU using RBCs processed and stored with the Hemanext ONE® system in Bergen, Norway as part of a post-market clinical study.
2022
Recent Posts
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®
- Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth